The FDA issued its first stamp of approval for a cell or gene therapy back in 2017 to Novartis' Kymriah. | The gene therapy ...

United Therapeutics' pipeline and Tyvaso DPI drive strong growth. Read why UTHR stock offers substantial upside with ...

Presbyopia is an age-related refractive condition marked by a gradual decline in near vision, typically emerging between ages 40 and 60. It results from the lens ...

Inc. ( an integrated pharmaceutical company dedicated to the worldwide development and commercialization of impactful ...

As drugmakers take lessons from oncology in developing CAR T cells for other diseases, they must contend with risks that ...

Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company developing innovative medicines for ...

The global neuroendocrine carcinoma treatment market is poised for substantial growth, with revenue expected to reach USD ...

Royalty Pharma inaugural Prize for Impact in Healthcare awarded to Michael Milken, the founder of the Milken Institute, Faster Cures & the ...

It's the superstars of one of B&T's favourite channels - brand experience. Or brand experience with the free sample.

Detailed price information for Royalty Pharma Plc Cl A (RPRX-Q) from The Globe and Mail including charting and trades.

Afqlir is indicated to treat various retinal diseases, including neovascular age-related macular degeneration (nAMD) ...